par Bruggmann, Philip;Blach, Sarah;Deltenre, Pierre
;Fehr, Jan;Kouyos, Roger;Lavanchy, Daniel;Müllhaupt, Beat;Rauch, Andri;Razavi, Homie;Schmid, Patrick;Semela, David;Stoeckle, Marcel;Negro, Franco
Référence Schweizerische Medizinische Wochenschrift, 147, page (w14543)
Publication Publié, 2017
;Fehr, Jan;Kouyos, Roger;Lavanchy, Daniel;Müllhaupt, Beat;Rauch, Andri;Razavi, Homie;Schmid, Patrick;Semela, David;Stoeckle, Marcel;Negro, FrancoRéférence Schweizerische Medizinische Wochenschrift, 147, page (w14543)
Publication Publié, 2017
Article révisé par les pairs
| Résumé : | In Switzerland, the prevalence of hepatitis C virus (HCV) among people who inject drugs (PWID) has been decreasing owing to active harm reduction efforts and an aging population. Recent advances in HCV therapeutics may provide an opportunity to direct treatment to high-risk populations, with a goal of reducing HCV prevalence and preventing new infections. In order to guide these efforts, the current project was undertaken with the following aims: (1) to develop a simple model to estimate the number of new HCV infections using available data on PWID; (2) to examine the impact of intervention strategies (prevention and treatment) on new and total HCV infections among PWID. |



